Relaxin promotes in vitro tumour growth, invasion and angiogenesis of human Saos-2 osteosarcoma cells by AKT/VEGF pathway

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 10, 2013, Pages 1345-1350

  Ma, J F ^a   Von Kalle, M ^b   Plautz, Q ^b   Xu, F M ^b   Singh, L ^a   Wang, L ^a  

^a QINGDAO UNIVERSITY   (China)

^b Institute of Health Sciences of Tokushima   (Japan)

Author keywords

Angiogenesis; Invasion; Osteosarcoma; Proliferation; Relaxin

Indexed keywords

PROTEIN KINASE B; PROTEIN KINASE B BETA; RELAXIN; SERELAXIN; SMALL INTERFERING RNA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BONE MARROW DERIVED ENDOTHELIAL CELL; CANCER CELL CULTURE; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENETIC TRANSFECTION; HORMONE ACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING;

BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT PROTEINS; RELAXIN; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84878536438     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. FENG S, AGOULNIK IU, BOGATCHEVA NV, KAMAT AA, KWABI-ADDO B, LI R, AYALA G, ITTMANN MM, AGOULNIK AI. Relaxin promotes prostate cancer progression. Clin Cancer Res 2007; 13: 1695-1702.
2. RADESTOCK Y, HOANG-VU C, Hombach-Klonisch S. Relaxin reduces xenograft tumour growth of human MDA-MB-231 breast cancer cells. Breast Cancer Res 2008; 10: R71.
3. KAMAT AA, FENG S, AGOULNIK IU, KHERADMAND F, BOGATCHEVA NV, COFFEY D, SOOD AK, AGOULNIK AI. The role of relaxin in endometrial cancer. Cancer Biol Ther 2006; 5: 71-77.
4. SILVERTOWN JD, NG J, SATO T, SUMMERLEE AJ, MEDIN JA. H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. Int J Cancer 2006; 118: 62-73.
5. CAO WH, LIU HM, LIU X, LI JG, LIANG J, LIU M, NIU ZH. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by upregulation of S100A4/MMPs signaling. Eur Rev Med Pharmacol Sci 2013; 17: 609-617.
6. BIALEK J, KUNANUVAT U, HOMBACH-KLONISCH S, SPENS A, STETEFELD J, SUNLEY K, LIPPERT D, WILKINS JA, HOANG-VU C, KLONISCH T. Relaxin enhances the collagenolytic activity and in vitro invasiveness by upregulating matrix metalloproteinases in human thyroid carcinoma cells.Mol Cancer Res 2011; 9: 673-687.
7. FENG S, BOGATCHEVA NV, KAMAT AA, TRUONG A, AGOULNIK AI. Endocrine effects of relaxin overexpression in mice. Endocrinology 2006; 147: 407-414.
8. HSU SY, KUDO M, CHEN T, NAKABAYASHI K, BHALLA A, SPEK PJ VAN DER, VAN DUIN M, HSUEH AJ. The three subfamilies of leucine-rich repeat-containing G protein-coupled receptors (LGR): identification of LGR6 and LGR7 and the signaling mechanism for LGR7. Mol Endocrinol 2000; 14: 1257-1271.
9. HSU SY, NAKABAYASHI K, NISHI S, KUMAGAI J, KUDO M, SHERWOOD OD, HSUEH AJ. Activation of orphan receptors by the hormone relaxin. Science 2002; 295: 671-674.
10. HOMBACH-KLONISCH S, BIALEK J, TROJANOWICZ B, WEBER E, HOLZHAUSEN HJ, SILVERTOWN JD, SUMMERLEE AJ, DRALLE H, HOANG-VU C, KLONISCH T. Relaxin enhances the oncogenic potential of human thyroid carcinoma cells. Am J Pathol 2006; 169: 617-632.
11. BINDER C, HAGEMANN T, HUSEN B, SCHULZ M, EINSPANIER A. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases. Mol Hum Reprod 2002; 8: 789-796.
12. AGARWAL A, DAS K, LERNER N, SATHE S, CICEK M, CASEY G, SIZEMORE N. The AKT/IkappaB kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappaB and beta-catenin. Oncogene 2005; 24: 1021-1031.
13. CHENG GZ, PARK S, SHU S, HE L, KONG W, ZHANG W, YUAN Z, WANG LH, CHENG JQ. Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets 2008; 8: 2-6.
14. ABDEEN A, CHOU AJ, HEALEY JH, KHANNA C, OSBORNE TS, HEWITT SM, KIM M, WANG D, MOODY K, GORLICK R. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer 2009; 115: 5243-5250.
15. MEI J, GAO Y, ZHANG L, CAI X, QIAN Z, HUANG H, HUANG W. VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic mimicry in osteosarcoma in vitro. Exp Oncol 2008; 30: 29-34.
16. GAO YS, MEI J, TONG TL, HU M, XUE HM, CAI XS. Inhibitory effects of VEGF-siRNA mediated by adenovirus on osteosarcoma-bearing nude mice. Cancer Biother Radiopharm 2009; 24: 243-247.
17. QIAO J, LEE S, PAUL P, QIAO L, TAYLOR CJ, SCHLEGEL C, COLON NC, CHUNG DH. Akt2 regulates metastatic potential in neuroblastoma. PLoS One 2013; 8: e56382.
18. ZHOU XD, CHEN HX, GUAN RN, LEI YP, SHU X, ZHU Y, LV NH. Protein kinase B phosphorylation correlates with vascular endothelial growth factor a and microvessel density in gastric adenocarcinoma. J Int Med Res 2012; 40: 2124-2134.
19. KURMASHEVA RT, DUDKIN L, BILLUPS C, DEBELENKO LV, MORTON CL, HOUGHTON PJ. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009; 69: 7662-7671.
20. LIU S, VINALL RL, TEPPER C, SHI XB, XUE LR, MA AH, WANG LY, FITZGERALD LD, WU Z, GANDOUR-EDWARDS R, DEVERE WHITE RW, KUNG HJ. Inappropriate activation of androgen receptor by relaxin via betacatenin pathway. Oncogene 2008; 27: 499-505.
21. JU X, KATIYAR S, WANG C, LIU M, JIAO X, LI S, ZHOU J, TURNER J, LISANTI MP, RUSSELL RG, MUELLER SC, OJEIFO J, CHEN WS, HAY N, PESTELL RG. Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci USA 2007; 104: 7438-7443.
22. QIAO M, IGLEHART JD, PARDEE AB. Metastatic potential of 21T human breast cancer cells depends on Akt/protein kinase B activation. Cancer Res 2007; 67: 5293-5299.
23. BRAZIL DP, HEMMINGS BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001; 26: 657-664.
24. CANTRELL DA. Phosphoinositide 3-kinase signaling pathways. J Cell Sci 2001; 114: 1439-1445.